CompoundAtlas
Sign in

Tirzepatide

81
evidence score
fat loss
Prescription Only
185 studies
MounjaroZepboundLY3298176+1 more

Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In the SURMOUNT trials, tirzepatide 15mg produced ~22.5% average weight loss over 72 weeks — the greatest pharmacological weight reduction ever demonstrated in a pivotal trial. GIP agonism adds metabolic benefits beyond GLP-1 alone, including adipocyte sensitization and muscle preservation. Superior efficacy vs. semaglutide in head-to-head trials (SURPASS-2).

Evidence

Strong evidence

Safety

Unknown safety profile

Clinical Status

Approved

Research Sync

Feb 19, 2026

Dosing

Typical
10 mg
2.5 mgRange15 mg
FrequencyOnce weekly subcutaneous

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~5 days
OnsetAppetite suppression within days; full effect over months
DurationOngoing; weight regain begins within weeks of stopping
Routes
subcutaneous

Evidence Score

81
Level A — Strong
185 studies indexed · 18 meta-analyses
Scoring Factors
Volume(40%)~45/100
Quality(30%)~59/100
Sample Size(10%)~100/100
Consistency(10%)~100/100
Replication(5%)~100/100
Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Tirzepatide is currently categorized as a fat loss compound.

Evidence is strong (81/100) with a relatively mature body of research (185 indexed studies).

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Dual GLP-1/GIP receptor agonist; GIP agonism sensitizes adipocytes and augments incretin effect beyond GLP-1 alone

Practical Context

Strongest current signals

  • Level B: People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
  • Level B: Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
  • Level B: Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.

Elevated caution signals

2 severe/high side effect flags

Compound Profile